Close Menu

NEW YORK – Meridian Bioscience reported on Friday that its fiscal first quarter revenues decreased 8 percent year over year partially due to lower contract pricing for certain gastrointestinal products.

For the three months ended Dec. 31, 2019 the firm reported revenues of $47.4 million, down from $51.5 million a year ago. Meridian missed the average Wall Street estimate of $48.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.